Nuveen’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-285,757
| Closed | -$9.76M | – | 3306 |
|
|
2022
Q2 | $9.76M | Sell |
285,757
-8,171
| -3% | -$363K | ﹤0.01% | 1528 |
|
|
2022
Q1 | $8.22M | Sell |
293,928
-100,295
| -25% | -$3.37M | ﹤0.01% | 1769 |
|
|
2021
Q4 | $15.1M | Sell |
394,223
-17,192
| -4% | -$769K | ﹤0.01% | 1420 |
|
|
2021
Q3 | $32.1M | Buy |
411,415
+57,711
| +16% | +$4.11M | 0.01% | 943 |
|
|
2021
Q2 | $27.6M | Buy |
353,704
+152,253
| +76% | +$11.3M | 0.01% | 1125 |
|
|
2021
Q1 | $19.1M | Buy |
201,451
+4,816
| +2% | +$573K | 0.01% | 1359 |
|
|
2020
Q4 | $24M | Buy |
196,635
+7,736
| +4% | +$848K | 0.01% | 1135 |
|
|
2020
Q3 | $16.5M | Buy |
188,899
+29,544
| +19% | +$2.06M | 0.01% | 1187 |
|
|
2020
Q2 | $10.3M | Buy |
159,355
+38,494
| +32% | +$2.22M | ﹤0.01% | 1466 |
|
|
2020
Q1 | $5.4M | Buy |
120,861
+12,218
| +11% | +$649K | ﹤0.01% | 1675 |
|
|
2019
Q4 | $6.77M | Buy |
108,643
+92,035
| +554% | +$4.38M | ﹤0.01% | 1828 |
|
|
2019
Q3 | $624K | Hold |
16,608
| – | – | ﹤0.01% | 2879 |
|
|
2019
Q2 | $676K | Buy |
+16,608
| New | +$592K | ﹤0.01% | 2896 |
|
Nuveen's TPTX Position: Q3 2022 in Review
Nuveen sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 285,757 shares — an estimated $9.76M sold.
Nuveen first reported a position in TPTX in Q2 2019 and held it in 13 quarters. The position peaked at $32.1M in Q3 2021. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.
- Nuveen reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
- Nuveen sold 285,757 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $9.76M.
- Nuveen first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 13 quarters.
- Nuveen's Turning Point Therapeutics, Inc. Common Stock position peaked at $32.1M in Q3 2021.
- 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.
Based on Nuveen's 13F filing for Q3 2022, filed 14 Nov 2022.